Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease

✍ Scribed by H. Biesemeyer; H. P. Ludin; E. Ringwald

• Publisher: Springer
• Year: 1983
• Tongue: English
• Weight: 279 KB
• Volume: 230
• Category: Article
• ISSN: 0340-5354
• DOI: 10.1007/bf00313593

✦ Synopsis

Twenty patients with advanced progressing Parkinson's disease have been treated with the 8-alpha-ergoline CU 32-085 in combination therapy for 3 months. With a mean daily dose of 12.65 mg, CU 32-085 together with levodopa plus a decarboxylase inhibitor produced a significant reduction in akinesia, rigor and tremor. Adverse reactions were rare and mild; in one case the drug was discontinued because of dyskinetic movements. Many of the pre-existing side effects were reduced or eliminated, particularly the involuntary movements and the levodopa response swings. The compound was considered useful in the treatment of advanced, progressing Parkinson's disease.